Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Yisheng Cleared to Start China Phase III Trial of PIKA Rabies Vaccine

publication date: Oct 9, 2018

Yisheng Biopharma, a Beijing immunomodulatory company, reported the CFDA will allow a Phase III trial of its PIKA® rabies vaccine. Yisheng has completed Phase I and II studies of the vaccine in Singapore and now plans a pivotal Phase III trial in Southeast Asia countries, with enrollment beginning in 2019. The company developed the rabies vaccine using its proprietary toll-like receptor-3 (TLR-3) immunomodulating technology, which Yisheng believes will eventually result in a best-in-class product. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital